Prometheus Bio Taps Thierry Dervieux as Chief Development Officer

Prometheus Biosciences on Tuesday said it has appointed Thierry Dervieux as chief development officer, diagnostics, and medical laboratory director. The San Diego-based biotech, created this summer through the acquisition of Prometheus Laboratories by Precision IBD, is working to create new drugs and companion diagnostics for people with gastroenterology disorders and autoimmune diseases.

Dervieux was most recently chief scientific officer and medical director at Exagen Diagnostics (NASDAQ: [[ticker:XGN]]). Prior experience includes stints at Cypress Bioscience and Proprius Pharmaceuticals (acquired by Cypress)—and at Prometheus Bio predecessor Prometheus Labs, as principal scientist and director of R&D.

Author: Sarah de Crescenzo

Sarah is Xconomy's San Diego-based editor. Prior to joining the team in 2018, she wrote about startups, tech and finance at the San Diego Business Journal. Her decade of full-time news experience includes coverage of subjects including campaign finance, crime and courts as a reporter and editor at outlets throughout California, including the Orange County Register. She earned a bachelor's degree in English Literature at UC San Diego, where she wrote for the student newspaper and played collegiate lacrosse. In 2019, she earned an MBA at UC Irvine.